Sage’s Pipeline Prospects Narrow Further As Dalzanemdor Fails In Huntington’s

Third And Final Indication For NMDA Modulator

 
• By Mandy Jackson
  
After building up a mid-stage R&D pipeline, all four of Sage's planned 2024 readouts were negative. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from Scrip